Login Register
icon_bulk_orderBulk order Acrobiosystems for English
Recombinant Proteins ClearClear history
Recombinant Proteins CloseClose
Browse Products By Molecule Name a-zA-Z
GMP IL-15 NEW |Omicron specific antibody Hot |Claudin 18.2 |CD3 |GPCRs
0
There is no goods in the shopping cart !
My Cart
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Insights
News
Insights
Promotion
Exhibitions
[Inspiring Target] Therapeutic Potential of Complement in Inflammation, Cancer, and COVID-19
The complement system, also known as the complement cascade, is an essential part of the innate immune system and plays a crucial role in defense against microbial infection and clearance of immune complexes and injured cells. Despite the lack of specificity of the components of the acquired immune
2022/05/16     Read: 264
LILRB + HLA-G, A New Ground-breaking Immunotherapy Combination
Immune-Onc Therapeutics released their research of io-108, a novel clinical-stage myeloid checkpoint inhibitor targeting LILRB2 (ILT4), at the American Association for Cancer Research (AACR) 2022 Annual Meeting. IO-108 promotes innate and adaptive anti-cancer immunity in preclinical models, and it i
2022/05/16     Read: 48
SSTR2, a potential therapeutic target for cancer
SSTR2(Somatostatin Receptor2) is a member of the G protein-coupled receptor (GPCR) family and is a seven-pass transmembrane protein with the N-terminal extracellular and the C-terminal intracellular. Since SSTR2 is highly expressed in neuroendocrine tumors (NETs), SSTR2 is the key target for the tre
2022/05/16     Read: 44
[Newly Launched] Three anti-IFN γ antibodies in ACRO’s “mAb Matrix”
ACROBiosystems has established an antibody product line named "mAb matrix". The "antibody matrix" series products are characterized with high specific and high sensitivity, and they are suitable for the methodology construction of both diagnosis and the entire process in the biopharmaceutical R&D, h
2022/05/06     Read: 119
Choose the development strategy of anti-idiotypic antibody to seize the advantage of PK/ADA assay
Immunogenicity (ADA) studies and pharmacokinetic (PK) analysis are critical in developing biopharmaceuticals. Anti-idiotypic antibodies are the key tool reagents for PK/ADA assay. This article summarizes the development strategies of anti-idiotypic antibodies for different types of biological drugs
2022/04/29     Read: 156
Regulatory Requirements of Cell and Gene Therapy
Cell and gene therapy (CGT) had developed rapidly since 2017 when two CAR-T cell therapy drugs were approved by FDA. However, quality research and quality control are more complicated due to the large heterogeneity in the cell source, type, and in vitro operation of cell and gene therapy products. F
2022/04/25     Read: 271
Classical, Potential, and Innovative Therapeutic Strategies for Brain Tumors
Brain tumors account for approximately 1.35% of all malignancies and 29.5% of cancer-related deaths. As compared to other types of tumors, whether malignant or not, brain tumors often have a more lasting and severe impact on the patients’ life quality. To prevent permanent brain damage and death, ea
2022/04/25     Read: 217
Inspiring target DLL3: For variety of lung cancer therapeutic methods development
DLL3 is a member of the Notch receptor ligands family and plays a crucial role in Notch signaling. It involves multiple processes of growth and development, such as differentiation of pluripotent progenitor, apoptosis, cell proliferation, and formation of cell boundaries. It has aroused people's
2022/04/22     Read: 583
Multiple Sclerosis: Etiology, Pathology, Pathogenesis and Therapeutic Drugs
Multiple sclerosis(MS）is an immune-mediated inflammatory demyelinating disease of the central nervous system. There are approximately 2 million MS patients worldwide, and it is the most common cause of permanent disability in young adults other than traumatic brain injury, resulting in a large socio
2022/04/01     Read: 1008
[Inspiring Target] Breakthroughs of targeting Claudin 6 in mAb, bsAb, ADC, CAR-T cell therapy
Claudin 6 is strictly silenced in healthy adult tissues, but aberrantly activated in various solid tumors with high medical needs, showing high levels of expression. Therefore, Claudin 6 is considered as a promising target for cancer immunotherapy. The research on different drug types targeting Clau
2022/03/30     Read: 761
More

This web search service is supported by Google Inc.

totop
Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
Email
Email
order@acrobiosystems.com
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA
linkedin twitter facebook youtube

Leave a message

Copyright © 2017 ACROBiosystems. All Rights Reserved
中文网站|Related Links|Privacy Policy|Terms and Conditions|Legal|Sitemap